Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology Launches Small Molecule Compound Library Access Scheme

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Subset of compound library to be made available to academic researchers free of charge.

MRC Technology has announced the launch of a scheme under which it will provide access to a representative subset of 9,000 compounds from its 150,000 small molecule compound library to academic research institutes free of charge.

The scheme has been launched by MRC Technology to provide academics with a high quality compound library for screening, to reduce academic spend on libraries less suited to screening, and to encourage groups to tap into MRC Technology’s drug discovery expertise for research programmes.

Under the terms of the scheme, participating academics will receive the 9,000 compounds in plate format and in return MRC Technology will have first refusal on collaboration agreements for any drug development programmes resulting from screens of the compound library.

Assay data will be jointly owned by MRC Technology and the research institute, giving MRC Technology a better understanding of how its library is performing against a diverse range of targets and enabling further enhancement of the library through an iterative process.

MRC Technology’s compound library has been built and curated by its medicinal chemistry and computational chemistry scientists.

The library includes 100,000 high quality, diverse, drug-like compounds with hit-like properties, with an additional 50,000 compounds in subsets targeted to specific protein classes.

The 9,000 compounds available through the scheme have been chosen to represent a cross-section of the full library.

Institutes joining the scheme will also benefit from access to advice on suitable assay design and screening formats, and optimization of screening hits, from MRC Technology’s team of scientists.

“We have seen an increase in assay throughput within academic research institutes, due to the availability of affordable small-scale robotics,” said Justin Bryans, Director of Drug Discovery at MRC Technology.

Bryans continued, “By offering access to our compound library with no fees attached, our aim is to stimulate drug discovery within the academic field by enabling these laboratories to carry out high quality, medium throughput screens and to potentially further develop any hits in collaboration with MRCT.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology and Yabao Pharmaceuticals Announce Exclusive Partnership
Partnership in China to develop novel therapeutics for Parkinson’s disease.
Friday, November 28, 2014
Charities Pledge to Inject Millions to Jump Start Drug Development for Brain Diseases
MRC Technology to lead Neurodegeneration Medicines Acceleration Programme to uncover promising drugs in pharma libraries.
Tuesday, November 18, 2014
MRC Technology and Proximagen Collaborate
Project will investigate a small molecule solution for Macrophage migration inhibitory factor.
Monday, October 13, 2014
MRC Technology Sells its MCRs Programme to Pfizer
Small molecules developed in collaboration with Queen Mary University of London.
Thursday, June 19, 2014
MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
Initiative brings together global expertise to streamline drug discovery.
Wednesday, May 14, 2014
MRC Technology and EMBLEM Collaborate to Streamline Drug Development
Initiative strengthens drug development and commercialization network.
Monday, April 15, 2013
MRC Technology Forms Alliance with World Leading Translational Research Centres
The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network.
Monday, January 21, 2013
MRC Technology and CAS Collaborate to Identify New Targets for Drug Discovery
Initiative brings together global expertise to streamline drug discovery.
Friday, November 30, 2012
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!